Short Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Rises By 9.7%

Ikena Oncology, Inc. (NASDAQ:IKNA) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 90,600 shares, a growth of 9.7% from the November 15th total of 82,600 shares. Based on an average daily trading volume, of 58,300 shares, the short-interest ratio is currently 1.6 days. Currently, 0.3% of the shares of the company are short sold.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on IKNA shares. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Ikena Oncology in a research note on Monday, November 11th. Wedbush reiterated a “neutral” rating and set a $2.00 price target on shares of Ikena Oncology in a research report on Thursday, November 7th.

Institutional Trading of Ikena Oncology

Hedge funds have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Ikena Oncology in the second quarter valued at approximately $30,000. BBR Partners LLC purchased a new position in shares of Ikena Oncology during the second quarter worth $33,000. AQR Capital Management LLC purchased a new position in shares of Ikena Oncology in the second quarter valued at approximately $36,000. FMR LLC boosted its position in Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after buying an additional 18,607 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Ikena Oncology during the 2nd quarter worth $75,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

Ikena Oncology Stock Down 2.4 %

IKNA opened at $1.61 on Tuesday. The company has a market cap of $77.70 million, a PE ratio of -1.31 and a beta of 0.49. Ikena Oncology has a twelve month low of $1.22 and a twelve month high of $2.32. The company has a 50-day moving average price of $1.70 and a 200 day moving average price of $1.70.

Ikena Oncology (NASDAQ:IKNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.08. As a group, sell-side analysts expect that Ikena Oncology will post -0.91 earnings per share for the current year.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.